SCHEDULE: 683 Capital Discloses 3.9% Stake in Gossamer Bio

683 Capital Management, LLC and its affiliates have disclosed a 3.9% beneficial ownership stake in Gossamer Bio, Inc., comprising common stock and exercisable warrants.

Summary

• 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman collectively reported beneficial ownership of 9,331,304 shares of Gossamer Bio, Inc. common stock.
• This ownership represents approximately 3.9% of the outstanding common stock.
• The stake includes 5,000,000 shares of common stock and warrants to purchase an additional 4,331,304 shares, which are currently exercisable.
• The percentage is calculated based on 234,696,281 shares outstanding as of March 10, 2026, plus the 4,331,304 shares issuable from warrants held by the reporting persons.
• The reporting persons certified that the securities were not acquired for the purpose of changing or influencing control of Gossamer Bio, Inc., except for activities related to a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates an institutional investor has taken a significant, albeit passive, stake in Gossamer Bio, which can be interpreted as a vote of confidence.

Positives

• A significant institutional investor, 683 Capital Management, LLC, has taken a notable stake in Gossamer Bio, potentially signaling confidence in the company's long-term prospects.
• The inclusion of exercisable warrants suggests a potential for increased future ownership and a long-term investment horizon.

Negatives

• The 3.9% stake is below the 5% threshold that would typically trigger more activist-oriented disclosures (Schedule 13D), indicating a passive investment approach for now.

Risks

• The filing itself does not detail specific risks related to Gossamer Bio's operations or financial health; it is a disclosure of ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Gossamer Bio, Inc. or the reporting persons regarding the company's future performance or strategic direction, beyond the nature of the investment.

Management Comments

• The filing includes a certification from the reporting persons that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes. For a biotechnology company like Gossamer Bio, attracting institutional investment can be a positive signal, especially given the capital-intensive nature of drug development. While a 3.9% stake is not typically considered an activist position, it represents a meaningful vote of confidence from a sophisticated investor.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional ownership in biotechnology companies is common, with many funds specializing in the sector.
• A 3.9% stake from a firm like 683 Capital Management, LLC, which is known for its investment activities, aligns with typical institutional portfolio allocations in growth-oriented sectors.
• This level of ownership is generally considered a passive investment, unlike larger stakes (e.g., 5% or more) that might signal a more active role in corporate governance or strategic direction, as seen with activist funds like Starboard Value or Elliott Management in other industries.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Management: Awareness of a notable institutional holder may influence strategic decisions, though the disclosed intent is passive.

Next Steps

• The filing does not explicitly mention future actions or milestones for Gossamer Bio or the reporting persons, beyond the ongoing beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal. However, it is a passive ownership disclosure (Schedule 13G) and does not provide new operational or financial performance data for Gossamer Bio. Therefore, without additional fundamental analysis of Gossamer Bio's business, products, and financials, a 'hold' recommendation is appropriate, acknowledging the institutional confidence while awaiting further operational updates.

Keywords

Gossamer Bio, GBIO, 683 Capital Management, Ari Zweiman, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Common Stock, Warrants